Health Care Legislation, Regulation, and Investigations after the Midterms

If control of Congress shifts after the midterms, health care and life sciences companies should prepare for a potential wave of congressional inquiries or investigations, such as scrutiny of companies that reached settlements with the current Administration. From possible oversight hearings on FDA, CDC, and HHS to impact on the Medicaid cuts and ACA reforms, the balance of power in Congress will shape what comes next. A divided Congress may mean legislative gridlock, while the Trump Administration is likely to lean more heavily on regulation to advance its priorities.

Join Reed Smith for an analysis of the election results and what they may mean for your business. We'll look at the lame-duck session, the outlook for the new Congress, and the regulatory and enforcement changes to watch. You'll leave with practical insights to help you plan for the months ahead.